<p>Assembly Biosciences, Inc.（納斯達克代碼：ASMB - 免費報告）- HC Wainwright 的股票研究分析師在 11 月 13 日（星期四）向投資者發佈的研究報告中下調了 Assembly Biosciences 的 2027 財年每股收益（EPS）預期。HC Wainwright 分析師 P. Trucchio 現在預計這家生物製藥公司將在該年度發佈每股收益 1.44 美元，低於之前預測的 1.67 美元。HC Wainwright 對該股票給予 “買入” 評級，目標價為 50.00 美元。Assembly Biosciences 當前全年的共識收益預期為每股（6.87 美元）。HC Wainwright 還對 Assembly Biosciences 的 2029 財年收益進行了預估，預計為每股 3.09 美元。</p>
<p>Assembly Biosciences（納斯達克代碼：ASMB - 獲取免費報告）最近在 11 月 10 日（星期一）發佈了季度收益數據。這家生物製藥公司報告該季度每股收益為（0.72 美元），低於共識預期的（0.50 美元）22 美分。Assembly Biosciences 的淨利潤率為負 117.20%，股本回報率為負 149.01%。該公司該季度的收入為 1079 萬美元，而共識預期為 746 萬美元。</p>
<p>獲取 <strong>Assembly Biosciences</strong> 警報：</p>
<p>ASMB 已經成為多份研究報告的主題。Guggenheim 在 9 月 8 日（星期一）的研究報告中將 Assembly Biosciences 的目標價從 31.00 美元上調至 39.00 美元，並給予該公司 “買入” 評級。Citizens Jmp 在 9 月 24 日（星期三）的研究報告中開始覆蓋 Assembly Biosciences。他們給予該公司 “跑贏大盤” 評級，目標價為 38.00 美元。Zacks Research 在 8 月 19 日（星期二）的研究報告中將 Assembly Biosciences 的評級上調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Assembly Biosciences 股票的 “賣出（d-）” 評級。最後，JMP Securities 在 9 月 24 日（星期三）的報告中開始覆蓋 Assembly Biosciences 的股票。他們給予該公司 “市場跑贏” 評級，目標價為 38.00 美元。五位研究分析師對該股票給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat，Assembly Biosciences 目前的共識評級為 “適度買入”，平均目標價為 41.25 美元。</p>
<p><strong>獲取我們關於 ASMB 的最新研究報告</strong></p>
<h2>Assembly Biosciences 股票表現</h2>
<p>納斯達克代碼：ASMB 的股票在星期一開盤價為 36.71 美元。該股票的市值為 2.8164 億美元，市盈率為-6.58，貝塔值為 0.60。Assembly Biosciences 的 1 年最低價為 7.75 美元，1 年最高價為 37.71 美元。該公司的 50 日移動平均價格為 27.37 美元，200 日移動平均價格為 21.55 美元。</p>
<h2>對 Assembly Biosciences 的對沖基金看法</h2>
<p>幾家機構投資者最近買入和賣出了該股票的股份。American Century Companies Inc.在第一季度購買了 Assembly Biosciences 的新股份，價值約 113,000 美元。Acadian Asset Management LLC 在第一季度將其在 Assembly Biosciences 的股份增加了 42.1%。Acadian Asset Management LLC 現在擁有 23,027 股這家生物製藥公司的股票，價值 219,000 美元，此前在上個季度又購買了 6,823 股。Palumbo Wealth Management LLC 在第二季度將其在 Assembly Biosciences 的持股增加了 3.8%。Palumbo Wealth Management LLC 現在擁有 18,667 股這家生物製藥公司的股票，價值 338,000 美元，此前在此期間又購買了 681 股。Geode Capital Management LLC 在第二季度將其在 Assembly Biosciences 的股份增加了 6.9%。Geode Capital Management LLC 現在擁有 51,015 股這家生物製藥公司的股票，價值 925,000 美元，此前在上個季度又購買了 3,312 股。最後，Ellsworth Advisors LLC 在第三季度收購了 Assembly Biosciences 的新股份，價值 852,000 美元。目前 19.92% 的股票由機構投資者持有。</p>
<h2>關於 Assembly Biosciences</h2>
<p>（獲取免費報告）</p>
<p>Assembly Biosciences, Inc.是一家生物技術公司，開發用於治療病毒性疾病的治療候選藥物。它開發的 ABI-5366 是一種長效單純皰疹病毒（HSV）解旋酶 - 引物抑制劑，目前正在進行 1a/1b 期臨牀試驗，以治療複發性生殖器皰疹；ABI-1179 也在進行 1a/1b 期臨牀試驗，治療複發性生殖器皰疹；ABI-6250 是一種小分子口服生物可用的肝炎δ病毒入侵抑制劑，目前正在進行 1a 期臨牀試驗。</p>
<h2>精選文章</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Assembly Biosciences</li>
<li>投資於高市盈率成長股</li>
<li>4 只寒冷天氣股票，隨着冬季消費升温而購買</li>
<li>能源和石油股票解析</li>
<li>迪士尼股票下跌——收益是否為 YouTube TV 和解鋪平道路？</li>
<li>現在購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>Meta 的痛苦可能是你的收益：這是一個罕見的購買窗口嗎？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNNQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNNQg"/></p>
<p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Assembly Biosciences 嗎？</h2>
<p>在你考慮 Assembly Biosciences 之前，你會想聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Assembly Biosciences 並不在名單上。</p>
<p>雖然 Assembly Biosciences 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

Assembly生物科技

<p>HC Wainwright 分析師將 Assembly Biosciences 的 2027 財年每股收益預期從 1.67 美元下調至 1.44 美元，維持 “買入” 評級，目標價為 50 美元。目前全年的每股收益共識為 -6.87 美元。其他分析師的評級各不相同，整體共識為 “適度買入”，平均目標價為 41.25 美元。機構投資者在 ASMB 股票交易中活躍，開盤價為 36.71 美元，市值為 2.8164 億美元</p>

<p>Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - Equities research analysts at HC Wainwright lowered their FY2027 earnings per share (EPS) estimates for Assembly Biosciences in a research note issued to investors on Thursday, November 13th. HC Wainwright analyst P. Trucchio now anticipates that the biopharmaceutical company will post earnings of $1.44 per share for the year, down from their prior forecast of $1.67. HC Wainwright has a &#34;Buy&#34; rating and a $50.00 price target on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' FY2029 earnings at $3.09 EPS.</p>
<div class="lb-trans"><p>Assembly Biosciences, Inc.（納斯達克代碼：ASMB - 免費報告）- HC Wainwright 的股票研究分析師在 11 月 13 日（星期四）向投資者發佈的研究報告中下調了 Assembly Biosciences 的 2027 財年每股收益（EPS）預期。HC Wainwright 分析師 P. Trucchio 現在預計這家生物製藥公司將在該年度發佈每股收益 1.44 美元，低於之前預測的 1.67 美元。HC Wainwright 對該股票給予 “買入” 評級，目標價為 50.00 美元。Assembly Biosciences 當前全年的共識收益預期為每股（6.87 美元）。HC Wainwright 還對 Assembly Biosciences 的 2029 財年收益進行了預估，預計為每股 3.09 美元。</p>
</div><p>Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The biopharmaceutical company reported ($0.72) earnings per share for the quarter, missing the consensus estimate of ($0.50) by ($0.22). Assembly Biosciences had a negative net margin of 117.20% and a negative return on equity of 149.01%. The business had revenue of $10.79 million for the quarter, compared to the consensus estimate of $7.46 million.</p>
<div class="lb-trans"><p>Assembly Biosciences（納斯達克代碼：ASMB - 獲取免費報告）最近在 11 月 10 日（星期一）發佈了季度收益數據。這家生物製藥公司報告該季度每股收益為（0.72 美元），低於共識預期的（0.50 美元）22 美分。Assembly Biosciences 的淨利潤率為負 117.20%，股本回報率為負 149.01%。該公司該季度的收入為 1079 萬美元，而共識預期為 746 萬美元。</p>
</div><p>Get <strong>Assembly Biosciences</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Assembly Biosciences</strong> 警報：</p>
</div><p>ASMB has been the subject of a number of other research reports. Guggenheim increased their price objective on Assembly Biosciences from $31.00 to $39.00 and gave the company a &#34;buy&#34; rating in a research report on Monday, September 8th. Citizens Jmp assumed coverage on Assembly Biosciences in a research report on Wednesday, September 24th. They issued an &#34;outperform&#34; rating and a $38.00 price target for the company. Zacks Research raised Assembly Biosciences to a &#34;hold&#34; rating in a research note on Tuesday, August 19th. Weiss Ratings reaffirmed a &#34;sell (d-)&#34; rating on shares of Assembly Biosciences in a research note on Wednesday, October 8th. Finally, JMP Securities assumed coverage on shares of Assembly Biosciences in a report on Wednesday, September 24th. They issued a &#34;market outperform&#34; rating and a $38.00 target price for the company. Five research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Assembly Biosciences currently has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $41.25.</p>
<div class="lb-trans"><p>ASMB 已經成為多份研究報告的主題。Guggenheim 在 9 月 8 日（星期一）的研究報告中將 Assembly Biosciences 的目標價從 31.00 美元上調至 39.00 美元，並給予該公司 “買入” 評級。Citizens Jmp 在 9 月 24 日（星期三）的研究報告中開始覆蓋 Assembly Biosciences。他們給予該公司 “跑贏大盤” 評級，目標價為 38.00 美元。Zacks Research 在 8 月 19 日（星期二）的研究報告中將 Assembly Biosciences 的評級上調至 “持有”。Weiss Ratings 在 10 月 8 日（星期三）的研究報告中重申了對 Assembly Biosciences 股票的 “賣出（d-）” 評級。最後，JMP Securities 在 9 月 24 日（星期三）的報告中開始覆蓋 Assembly Biosciences 的股票。他們給予該公司 “市場跑贏” 評級，目標價為 38.00 美元。五位研究分析師對該股票給予 “買入” 評級，一位給予 “持有” 評級，一位給予 “賣出” 評級。根據 MarketBeat，Assembly Biosciences 目前的共識評級為 “適度買入”，平均目標價為 41.25 美元。</p>
</div><p><strong>Get Our Latest Research Report on ASMB</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 ASMB 的最新研究報告</strong></p>
</div><h2>Assembly Biosciences Stock Performance</h2>
<div class="lb-trans"><h2>Assembly Biosciences 股票表現</h2>
</div><p>Shares of NASDAQ:ASMB opened at $36.71 on Monday. The stock has a market capitalization of $281.64 million, a price-to-earnings ratio of -6.58 and a beta of 0.60. Assembly Biosciences has a 1-year low of $7.75 and a 1-year high of $37.71. The company has a 50 day moving average price of $27.37 and a 200 day moving average price of $21.55.</p>
<div class="lb-trans"><p>納斯達克代碼：ASMB 的股票在星期一開盤價為 36.71 美元。該股票的市值為 2.8164 億美元，市盈率為-6.58，貝塔值為 0.60。Assembly Biosciences 的 1 年最低價為 7.75 美元，1 年最高價為 37.71 美元。該公司的 50 日移動平均價格為 27.37 美元，200 日移動平均價格為 21.55 美元。</p>
</div><h2>Hedge Funds Weigh In On Assembly Biosciences</h2>
<div class="lb-trans"><h2>對 Assembly Biosciences 的對沖基金看法</h2>
</div><p>Several institutional investors have recently bought and sold shares of the stock. American Century Companies Inc. bought a new stake in shares of Assembly Biosciences during the 1st quarter worth about $113,000. Acadian Asset Management LLC lifted its stake in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 6,823 shares during the last quarter. Palumbo Wealth Management LLC boosted its holdings in shares of Assembly Biosciences by 3.8% during the 2nd quarter. Palumbo Wealth Management LLC now owns 18,667 shares of the biopharmaceutical company's stock worth $338,000 after buying an additional 681 shares during the period. Geode Capital Management LLC grew its stake in Assembly Biosciences by 6.9% in the 2nd quarter. Geode Capital Management LLC now owns 51,015 shares of the biopharmaceutical company's stock valued at $925,000 after buying an additional 3,312 shares during the last quarter. Finally, Ellsworth Advisors LLC acquired a new position in Assembly Biosciences during the 3rd quarter worth $852,000. 19.92% of the stock is currently owned by institutional investors.</p>
<div class="lb-trans"><p>幾家機構投資者最近買入和賣出了該股票的股份。American Century Companies Inc.在第一季度購買了 Assembly Biosciences 的新股份，價值約 113,000 美元。Acadian Asset Management LLC 在第一季度將其在 Assembly Biosciences 的股份增加了 42.1%。Acadian Asset Management LLC 現在擁有 23,027 股這家生物製藥公司的股票，價值 219,000 美元，此前在上個季度又購買了 6,823 股。Palumbo Wealth Management LLC 在第二季度將其在 Assembly Biosciences 的持股增加了 3.8%。Palumbo Wealth Management LLC 現在擁有 18,667 股這家生物製藥公司的股票，價值 338,000 美元，此前在此期間又購買了 681 股。Geode Capital Management LLC 在第二季度將其在 Assembly Biosciences 的股份增加了 6.9%。Geode Capital Management LLC 現在擁有 51,015 股這家生物製藥公司的股票，價值 925,000 美元，此前在上個季度又購買了 3,312 股。最後，Ellsworth Advisors LLC 在第三季度收購了 Assembly Biosciences 的新股份，價值 852,000 美元。目前 19.92% 的股票由機構投資者持有。</p>
</div><h2>About Assembly Biosciences</h2>
<div class="lb-trans"><h2>關於 Assembly Biosciences</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.</p>
<div class="lb-trans"><p>Assembly Biosciences, Inc.是一家生物技術公司，開發用於治療病毒性疾病的治療候選藥物。它開發的 ABI-5366 是一種長效單純皰疹病毒（HSV）解旋酶 - 引物抑制劑，目前正在進行 1a/1b 期臨牀試驗，以治療複發性生殖器皰疹；ABI-1179 也在進行 1a/1b 期臨牀試驗，治療複發性生殖器皰疹；ABI-6250 是一種小分子口服生物可用的肝炎δ病毒入侵抑制劑，目前正在進行 1a 期臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than Assembly Biosciences</li>
<li>Investing in the High PE Growth Stocks</li>
<li>4 Cold-Weather Stocks to Buy as Winter Spending Heats Up</li>
<li>Energy and Oil Stocks Explained</li>
<li>Disney Stock Drops—Will Earnings Pave Way for a YouTube TV Truce?</li>
<li>2 Fintech Stocks to Buy Now and 1 to Avoid</li>
<li>Meta’s Pain May Be Your Gain: Is This a Rare Buying Window?</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Assembly Biosciences</li>
<li>投資於高市盈率成長股</li>
<li>4 只寒冷天氣股票，隨着冬季消費升温而購買</li>
<li>能源和石油股票解析</li>
<li>迪士尼股票下跌——收益是否為 YouTube TV 和解鋪平道路？</li>
<li>現在購買的 2 只金融科技股票和 1 只應避免的股票</li>
<li>Meta 的痛苦可能是你的收益：這是一個罕見的購買窗口嗎？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QVNNQg" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=ASMB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Assembly Biosciences Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Assembly Biosciences 嗎？</h2>
</div><p>Before you consider Assembly Biosciences, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Assembly Biosciences 之前，你會想聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Assembly Biosciences wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師正在悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Assembly Biosciences 並不在名單上。</p>
</div><p>While Assembly Biosciences currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Assembly Biosciences 目前在分析師中獲得 “適度買入” 評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

HC Wainwright 發佈了對 Assembly Biosciences 2027 財年收益的預估